Post-transplant Cyclophosphamide (PTCy)

DRUG2 trials

Sponsors

National Cancer Institute (NCI), Hackensack Meridian Health

Conditions

Allogeneic Stem Cell Transplant RecipientHematopoietic Stem Cell TransplantationImmunodeficiency

Phase 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

RecruitingNCT05027945

National Cancer Institute (NCI)Hematopoietic Stem Cell Transplantation, Immunodeficiency

Start: 2023-02-23End: 2026-07-01Target: 54Updated: 2026-04-02

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

RecruitingNCT07214688

Hackensack Meridian HealthAllogeneic Stem Cell Transplant Recipient

Start: 2026-01-06End: 2032-01-01Target: 209Updated: 2026-03-23

Related Papers

Sustained donor engraftment and clinical remission after hematopoietic cell transplantation for vexas syndrome, but with observed toxicities: Results from a prospective phase II clinical Trial

Blood2025-11-03

Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome

Blood2023-11-024 citations